Industry News

Piramal Enterprises Ltd's Structured Finance Group, the non-real estate lending business, plans to provide customized lending solutions to companies across sectors and double its team as it seeks to expand its business aggressively. "Any promoter anywhere in India who wants money, wants flexibility and wants a good partner, should call on us. We want to become the first port of call for all companies, "said Khushru Jijina, managing director at Piramal Fund..."/>
Piramal's SFG plans aggressive expansion [Mint, New Delhi]
CCI approves Sanofi-Boehringer asset swap [Mint, New Delhi]
Teva Pharmaceutical Industries Ltd. in the New York court regarding the acquisition of the Mexican firm Rimsa will probably not be the only legal action Teva will have to conduct regarding this acquisition. Yesterday, the Central District Court received a request to file a derivative suit against Teva, company directors and executives, including CEO Erez Vigodman and CFO Eyal Desheh, and against Citigroup, which provided Teva with consultation..."/>
Shareholders sue Teva over Rimsa acquisition [Globes, Tel Aviv, Israel]
CEL-SCI Corporation announced today that it has received verbal notice from the U.S. Food and Drug Administration that its Multikine Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed."/>
CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study
GLOBAL NET LEASE/AMERICAN REALTY CAPITAL TRUST II TIE-UP A 45- day "go shop" period has expired in US-based REIT Global Net Lease, Inc.' s deal to acquire US-based REIT American Realty Capital Global Trust II, Inc. for approximately USD 247 m, the companies said. The companies entered into a definitive agreement on 8 August, in a deal by and among GNL, American Realty Capital Global..."/>
M and A Navigator: Deal pipeline 27 September
Natus Medical Inc. has entered into a definitive agreement to buy Danish hearing aid maker GN Store Nord A/S's GN Otometrics hearing and balance assessment business in an all cash transaction for USD 145 m, the company said. With annual revenue of approximately USD 110 m, Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software, currently being sold in..."/>
Natus to Acquire Hearing and Balance Assessment Firm GN Otometrics for USD 145m
Cambrex Corp. has agreed to acquire drug manufacturer PharmaCore Inc. for approximately USD 25 m, the company said. PharmaCore is a privately-owned company specialising in developing, manufacturing and scaling up small molecule APIs for clinical phase projects. It was founded in 1999 and occupies a 35,000 sq. ft."/>
Cambrex to Acquire Pharmaceutical Ingredients Maker PharmaCore for USD 25m
CBOE Holdings Inc.. The deal comes less than four years after Chicago-based CME Group agreed to buy the 156- year-old Kansas City Board of Trade."/>
Lenexa-based Bats Global Markets agrees to $3.2 billion buyout [The Kansas City Star]
UNIFIRST CLOSES USD 122 M ACQUISITION OF ARROW UNIFORM. US-based work uniforms and facility services provider UniFirst Corp. has completed its acquisition of US-based Arrow Uniform for approximately USD 122 m, the company said."/>
M and A Navigator: Deal pipeline –26 September
Rennova Health has a new woe: Its landlord wants $1.94 million in unpaid rent. In a lawsuit filed this week in Palm Beach County, property owner Reflect Co. LLC says Medytox Solutions, as Rennova was known until recently, is in default of its lease after missing an August rent payment on its headquarters at 400 Australian Ave. in West Palm Beach. Rennova, a medical testing firm, has been hemorrhaging money."/>
Best of Our Blogs: Rennova Health owes rent; holiday travel tips [The Palm Beach Post, Fla.]
Intrexon Corporation, a leader in synthetic biology, today announced that pursuant to New York Stock Exchange Rule 303 A.08 it granted Geno J. Germano an employment inducement award in connection with Mr. As Intrexon previously disclosed in a Current Report on Form 8- K filed on May 17, 2016, the Intrexon Compensation Committee approved the award to Mr. Germano of options to purchase an aggregate of 2,000,000 shares of the Company's common..."/>
Intrexon Grants Employment Inducement Award Pursuant to NYSE Rule 303A.08
RepliCel Life Sciences Inc., a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company. As announced in July, RepliCel's RCH-01 product, for the treatment of androgenetic alopecia, is now under clinical investigation at Tokyo Medical University Hospital and Toho University..."/>
RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
UnitedHealth Group, are taking immediate action to help people in western Wisconsin who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Western Wisconsin
Infinity Pharmaceuticals, Inc. today announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. Preliminary Phase 1 results from nine patients with advanced solid tumors show that the safety, pharmacokinetics and pharmacodynamics of IPI-549 monotherapy treatment appear favorable. Additionally, new preclinical data..."/>
Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of its lead 4-1 BB- based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference- Translating Science into Survival, taking place in New..."/>
Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Cigna will give it more market power, saving the insurer billions of dollars and reducing charges for customers. Department of Justice, which is seeking to stop the nation's second-largest health insurer from buying Bloomfield-based Cigna, argues that more leverage at a larger Anthem could hurt doctors and hospitals, and therefore hurt the quality of health care..."/>
Anthem Says Cigna Merger Will Cut Costs, Create Savings [The Hartford Courant]
CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its previously announced underwritten public offering of 2,250,000 shares of its common stock at a public offering price of $4.00 per share, before deducting underwriting discounts and commissions and estimated..."/>
CareDx Announces Closing of Public Offering of Common Stock
Navidea Biopharmaceuticals, Inc. today announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer effective September 22, 2016. The Board of Directors has also appointed Eric K. Rowinsky M.D., a Navidea board member since 2010, as Chairman of Navidea’ s Board, a position previously held by Dr."/>
Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer
Amgen today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts. LabCentral is an innovative, shared laboratory space designed as a launch pad for premier high-impact life-sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two..."/>
Amgen Opens Nomination Process For LabCentral Residency
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30- day option to purchase up to an additional..."/>
MyoKardia Announces Proposed Public Offering of Common Stock
Biodel Inc. today announced that its 2016 annual meeting of stockholders has been set for October 24, 2016. At that meeting, stockholders will vote on, among other things, matters necessary to complete Biodel's planned transaction with Albireo Limited pursuant to a previously announced share exchange agreement, including the issuance of shares of Biodel's common stock in the transaction and a proposed reverse stock split of Biodel's common stock at a..."/>
Biodel Announces 2016 Annual Meeting of Stockholders Set for October 24, 2016; Outlines Plan to Regain Compliance With Nasdaq Listing Requirements
Pfizer Inc.' s pending acquisition of small molecule biopharmaceutical company Medivation, Inc., the company said. Pfizer now expects to complete the acquisition in 3 Q16. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding..."/>
Pfizer Clears US Antitrust Hurdle in Acquisition of Medivation

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology689 Articles
Consumer Discretionary612 Articles
Financials556 Articles
Health Care395 Articles
Industrials390 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at